Issuu on Google+

FROM PRINCIPLES TO PRACTICE

Accelerating Vaccine Development, Advocacy and Access to Treatment Annual Report 2013

Our Mission is to reduce needless human suffering from vaccine-preventable and neglected tropical diseases (NTDs) by developing new vaccines, advocating increased use of existing vaccines and promoting expanded access to affordable medical treatments.

Table of Contents

3 Letter from the Chairman, CEO and President 4 Sabin’s Programs: A Multifaceted Approach to Global Health 9 Our 2013 Accomplishments at a Glance 10 Modeling Sabin’s Work around Our Beliefs 12 Major Funding Commitments Supporting Sabin Programs 14 From Laboratory to Field Trial: Developing Vaccines That Fight Poverty 20 Accelerating a Movement to End Neglected Diseases 24 Building the Foundation for Sustainable Immunization Programs 28 Partnering Abroad: Sabin Foundation Europe 30 Awards and Recognition 31 Board of Trustees and Senior Leadership 32 Financial Report 34 Thank You 36 Remembering a Global Health Hero

1

2

Letter from the Chairman, CEO and President

Securing the basic human right of good health remains out of reach for most of the two billion people living at or below the global poverty line. Yet, addressing the health needs of poor communities is essential for achieving equity, the best possible academic performance and economic prosperity. Despite significant progress in extending immunization coverage around the world, nearly 22 million children still are not receiving the vaccines they need to survive beyond the age of five. But there is cause for optimism: Economic growth has triggered greater investments in public health programs in low- and middle-income countries. The two decades since the Sabin Vaccine Institute (Sabin) was established have been marked by profound advances in the delivery of health solutions to the world’s poorest people. Deaths among children from preventable diseases such as polio, measles and rotavirus have fallen dramatically, thanks to improved access to available vaccines and the development of new ones. There has been a surge of low-income countries adopting national health plans – and the budgets to sustain them. Also, neglected tropical diseases (NTDs), which infect more than one in six people worldwide, are beginning to receive the level of political support and action that is proportional to the level of suffering they inflict. And two ambitious and broadly endorsed plans – the 2011 Global Vaccine Action Plan and the 2012 London Declaration on NTDs – provide us with the best roadmaps to date for closing remaining vaccine and NTD treatment gaps, using available tools and developing next generation treatments. But our shared commitment to reach our goals cannot waver as we advance toward control and elimination targets for many diseases, attainable for some diseases

by the end of this decade. There is always a real risk that reduced engagement and a drop in interest among multilateral and government institutions, foundations and philanthropists, as well as the general public, will stall progress. The next few years present the best opportunity we will have to achieve a knockout blow on some of the world’s most pernicious diseases. Missing this window should not be an option. We believe country ownership of public health programs is crucial to address existing vaccine and NTD treatment gaps in a sustainable manner. We must accelerate efforts to help countries reach the point where they support basic health initiatives out of their own national budgets, rather than relying on continued financial support from other nations or multilateral donors. Sabin’s core programs – the Sabin Vaccine Institute Product Development Partnership, the Global Network for Neglected Tropical Diseases and Vaccine Advocacy & Education – are all anchored to our goal of achieving country ownership by incorporating three principles into our work: education, partnerships and innovation. We are pleased to present Sabin’s 2013 annual report, which highlights the progress that has been made to close persistent health gaps by advocating greater political and public commitment for vaccine-preventable and neglected tropical diseases, and developing novel vaccines that will serve the world’s poor. We are grateful for your support and look forward to continuing our work together in the coming year.

Morton P. Hyman Chairman

Michael W. Marine, Ambassador (Ret.) CEO

Peter J. Hotez, M.D., Ph.D. President 3

Sabin’s Programs: A Multifaceted Approach to Global Health

With deep knowledge in advocacy and early-stage vaccine development for some of the world’s most pervasive diseases, Sabin is driven by the conviction that every dollar invested in preventing and treating these diseases improves quality of life, strengthens communities and boosts economies.

4

The Sabin Vaccine Institute (Sabin) was founded to continue the legacy of Dr. Albert B. Sabin, the developer of the oral polio vaccine and an ardent champion for ensuring the world’s most vulnerable populations receive access to essential medical solutions.

OUR THREE PROGRAMS

The Sabin Vaccine Institute Product Development Partnership, the Global Network for Neglected Tropical Diseases and Vaccine Advocacy & Education, support a multifaceted, coordinated approach to preventing, controlling and eliminating diseases through drug delivery and increased access to vaccines, research, advocacy, communications, and policy reform, working in collaboration with an extensive network of experts and decision-makers.

5

Sabin's Programs

The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) Vaccines hold the potential to end the threat of the most prevalent neglected tropical diseases (NTDs) forever. For the past 14 years, the Sabin PDP has been at the forefront of developing and testing vaccines to prevent or treat NTDs. It has been based at the Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development at Baylor College of Medicine in Houston since 2011. Led by our president, Dr. Peter Hotez, the Sabin PDP works closely with other academic institutions, governmental organizations and non-profit entities around the world to develop and test vaccines for a wide range of diseases afflicting the world’s poor. These include vaccine candidates for human hookworm infection, schistosomiasis, ascariasis, trichuriasis, leishmaniasis, Chagas disease, severe acute respiratory syndrome (SARS), onchocerciasis and West Nile virus. The Sabin PDP is an internationally recognized, comprehensive, low-cost model that serves as a business blueprint for the advancement of non profit vaccine research and development (R&D) and other

6

ongoing efforts to combat public health threats. Alongside partners in low- and middle-income countries, Australia, the U.S. and Europe, the Sabin PDP is applying science-based solutions to poverty reduction by conducting preclinical development, vaccine manufacturing and clinical testing of vaccine candidates. The Michelson Neglected Disease Vaccine Initiative, founded through the generous financial support of the Michelson Medical Research Foundation, supports a number of Sabin PDP activities and helps advance this innovative public-private partnership model to collaborate on preclinical development, vaccine manufacturing and clinical testing. The initiative supports the Human Hookworm Vaccine Discovery Program, the PanAnthelminthic Vaccine Discovery Program and the Schistosomiasis Vaccine Initiative.

Sabin's Programs

Global Network for Neglected Tropical Diseases (Global Network) NTDs infect 1.4 billion people worldwide, causing malnutrition, anemia, blindness and other disabilities that prevent children from attending school and keep adults from working. However, while the social and economic impact of NTDs is significant, treating these diseases is one of the lowest-cost health interventions available today. Because nearly all of the medicines to control and eliminate the most common NTDs have been donated by pharmaceutical companies, the annual global average cost of treatment is just 50 cents per person.

With the support of partner organizations such as the Bill & Melinda Gates Foundation, the Global Network serves as a common platform and unifying voice for the NTD community by crafting complex public health messaging for a range of audiences, educating policymakers and advocating greater investment in NTD programs by endemic and donor countries, including the U.S. and the UK, and elevating NTDs as a priority health issue through innovative public affairs practices and an award-winning advocacy campaign.

Established in 2006, the Global Network continues to play a leading role in building the public awareness, political commitment and funding necessary to achieve the objectives of the 2012 World Health Organization road map for NTD control; reach the goals of the London Declaration, an international agreement signed by private and public organizations and aimed at controlling and eliminating 10 NTDs by 2020; and support the 2013 World Health Assembly resolution on NTDs, all important milestones in the fight to control and eliminate these diseases worldwide.

7

Sabin's Programs

Vaccine Advocacy & Education

Providing universal access to life-saving vaccines continues to remain a global health challenge. Too many countries remain dependent on external partners to fund immunization programs, despite their rapidly growing economies. In addition, health practitioners often lack information about the newest vaccines— information that can make the programs more effective. Through our Vaccine Advocacy & Education program, we engage global leaders and public institutions to ensure new and underutilized vaccines are distributed and sustainably financed. By convening coalitions, hosting trainings and conferences and conducting new research, we ensure that policy and technical experts have the best available information on vaccinepreventable diseases to help them make informed decisions about introducing new vaccines and properly financing immunization programs. Our initiatives include the Coalition against Typhoid (CaT), a global forum of scientists and immunization experts from 29 organizations seeking to improve lowcost typhoid vaccine coverage in vulnerable populations. The Sustainable Immunization Financing (SIF) Program currently operates in 18 countries and is expanding to 8

four new countries, thanks to additional funding from the GAVI Alliance and the Bill & Melinda Gates Foundation. The SIF team works with health, finance and elected officials in low-income countries to increase budget allocations and increase country ownership of national immunization programs. Our newest initiative, the International Association of Immunization Managers (IAIM), seeks to build the first international professional organization of immunization managers to allow them to benefit from access to global best practices, peer-to-peer exchanges and access to professional trainings and tools. The world is close to having its first dengue fever vaccine, and our participation in the Dengue Vaccine Initiative has helped foster an environment where vaccine developers, implementers and regulators are prepared for an anticipated product release in 2015. Lastly, Sabin’s Vaccine Advocacy & Education program also hosts global symposia, journalist trainings and vaccinology courses that facilitate knowledge sharing and best practices on vaccine-preventable diseases such as pneumococcal, meningococcal and rotavirus.

2013 Accomplishments

Our 2013 Accomplishments at a Glance Sabin “20 Years” Original Graphics HOOKVAC CONSORTIUM

Sabin “20 Years” Original

PDP

Globe 1

Poliovirus

ADVOCACY TO PROTECT 30 MILLION PEOPLE

Created HOOKVAC, a new consortium of partners Led advocacy efforts in from the European Union, the U.S., the UK and across the U.S. and Africa that will Europe with specific PDP Globe 1 Poliovirus Measles Virus Partnership Globe 2 EXPLORATORY STAGE expand the Sabin PDP’s regional institutions SIF COLLOQUIUM Began the discovery of groundbreaking work like the African Union Held second biannual vaccine candidates against on a human hookworm Commission and colloquium on sustainable ascariasis and trichuriasis. vaccine by forging new Organization of American immunization financing in Sabin “20 Years” Original Graphics collaborations with small ResearchStates, and multilateral Dakar, Senegal. Partnership Globe 2 Meeting PRECLINICAL PHASE and medium enterprises organizations, such as the Synthesis Continued the preclinical in Europe for vaccine United Nations, to increase PEER-REVIEWED PAPERS phase for selected vaccine manufacturing and the first funding for effective Published more than candidates (Chagas clinical testing of a hookpolicies to treat, control 20 peer-reviewed papers disease, leishmaniasis, worm vaccine in Africa. and eliminate the seven supporting NTD vaccine Synthesis Innovation PDP Globe 1 Poliovirus Measles Virus SARS and West Nile virus). most common NTDs, R&D and sustainable benefitting more than immunization financing. Scott Melamed 2014 CLINICAL DEVELOPMENT 30 million people. Continued advancing MEETINGS AND hookworm and CELEBRITY VIDEO CONFERENCES CAMPAIGN schistosomiasis Convened almost 50 Partnership Globe 2 Meeting Research vaccines through LEADERSHIP ADVOCACY Launched a new NTD meetings and conferences clinical development. Participated in over 50 advocacy video with to advocate greater public lectures and renowned celebrities that funding and management INTERNATIONAL published 11 policy papers, received almost 600,000 for vaccine-preventable ASSOCIATION FOR and Sabin Innovation increased online views and raised diseases. Synthesis IMMUNIZATION MANAGERS media coverage for enough funds to treat Formed the first NTDs through online, millions of people. Scott Melamed 2014 international association radio, television, and print to provide immunization media interviews and managers around the op-ed placements. world with access to best practices, peer exchanges and program updates.

9

Meeting

Innovation

Modeling Sabin’s Work around Our Beliefs

• Health resources must be made available to every person in need. • Countries should set their own health priorities. • Countries must improve their ability to sustainably finance their own health programs.

10

Our Beliefs

Each one of Sabin’s programs embodies the principles of country ownership and empowerment. To achieve this, we incorporate three core tenets into our work: EDUCATION AND KNOWLEDGE SHARING is

the foundation of effective vaccine research and development and advocacy, and is an essential component as we engage global leaders to bring neglected health issues to the front of development agendas. Transparency, trust and strategic communication also are critical tools in our business, and we have seen over the years that convening the right decision makers, at the right time, can yield breakthrough results in policy environments that once looked unchangeable.

INNOVATION at Sabin extends beyond the complex

work that we undertake to develop novel vaccine candidates. We think it also means being nimble, looking for opportunities where most see challenges and coming up with new approaches to promote solutions to health issues. EFFECTIVE PARTNERSHIPS are absolutely essential to

fostering sustainable programs that embody a shared sense of ownership. Encouraging collaboration takes time and effort, but it produces enduring practices and policies that can evolve with broader political and socio-economic changes.

11

Major Funding Commitments

Major Funding Commitments Supporting Sabin Programs

VACCINE ADVOCACY & EDUCATION

Over the past five years, we have secured grant commitments totaling US $84.6 million. Some of our most significant grants are listed below.

THE GLOBAL NETWORK FOR NEGLECTED TROPICAL DISEASES

received US $7.1 million in grants for programs and events to advocate for immunization in 2013. Major grants over the past five years total $20.6 million and include:

has received US $39.4 million in grants since 2008 to conduct advocacy and resource mobilization efforts that leveraged US $164.5 million in resources for NTD treatment programs. Major grants include:

US $7.0 MILLION

US $4.8 MILLION

US $37.6 MILLION

US $750,000

over six years from the Bill & Melinda Gates Foundation to support the Coalition against Typhoid.

over three years from the Bill & Melinda Gates Foundation to support the Sustainable Immunization Financing program.

over two years from the Michelson Medical Research Foundation in support of the NTD Special Envoy Program.

US $4.9 MILLION

US $3.9 MILLION

over six years from the Bill & Melinda Gates Foundation to mobilize resources and conduct strategic advocacy work for NTD treatment programs.

over five years from the Bill & Melinda Gates Foundation to support the International Association of Immunization Managers.

from the GAVI Alliance to expand the Sustainable Immunization Financing program to new countries in Asia and Europe.

12

US $1 MILLION

over four years from the Hoffman Family Foundation in support of NTD treatment programs.

Major Funding Commitments

US $40.75 million

THE SABIN PDP received US $12.2 million in grants in 2013. Major grants over the past five years total $40.75 million and include:

US $12.1 MILLION

US $2.05 MILLION

over four years from the Bill & Melinda Gates Foundation to support the development of a human hookworm vaccine.

in funding from the National Institutes of Health, Texas Children’s Hospital, the Blavatnik Family Foundation, Morton and Chris Hyman and the Michelson Medical Research Foundation to support development of a schistosomiasis vaccine.

€6.0 MILLION (US $8.2 MILLION)

over four years from the European Commission for the HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, to develop and test the human hookworm vaccine in Africa. €5.9 MILLION (US $8.1 MILLION)

over four years from the Dutch Ministry of Foreign Affairs to support the development of the human hookworm vaccine.

US $39.4 million

US $2.0 MILLION

over four years from the Michelson Medical Research Foundation to launch the PanAnthelminthic Vaccine Discovery Program.

US $20.6 million

US $1.2 MILLION

in funding from the James Chao Family Foundation to the consortium led by Baylor College of Medicine for West Nile virus vaccine development and education activities.

US $6.2 MILLION

over five years from the National Institute of Allergy and Infectious Diseases to the consortium led by Baylor College of Medicine to develop a vaccine for severe acute respiratory syndrome (SARS).

US $900,000

in funding from the Carlos Slim Heath Institute to the consortium led by Baylor College of Medicine to support Chagas disease and leishmaniasis vaccine development programs.

13

From Laboratory to Field Trial:

Developing Vaccines That Fight Poverty

14

Sabin PDP

Through rigorous vaccine research and development (R&D), the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) is creating an environment that can support the introduction of and ready access to new vaccine products when they become available. And through its advocacy work, the Sabin PDP is working to put neglected tropical diseases (NTDs) – and the need to control and eliminate them – more prominently onto the global health and vaccine development agenda. Coalitions worldwide are adopting the Sabin PDP’s messaging and educating funders and policymakers about the need to develop these vaccines.

The Sabin PDP’s most advanced project, the Human Hookworm Vaccine Initiative (HHVI), builds on more than 14 years of research. This program is developing vaccine candidates alongside partners in endemic countries such as Brazil and Gabon, as well as in Europe and Australia. This large, interdisciplinary collaboration includes clinical, basic and translational scientists, not only focused on advancing safe, effective vaccines, but also building expertise and capacity for vaccine development among R&D institutions in other countries with the goal of developing sustainable industrial production of vaccines in endemic countries.

Sabin is addressing the threat of NTDs, such as hookworm, worldwide through rigorous R&D.

In 2013, the Sabin PDP continued Phase 1 clinical trials at a field site in Brazil evaluating the safety and efficacy of Na-GST-1, one of our hookworm vaccine candidates. We also began Phase 1 clinical trials for Na-GST-1, as well as a second hookworm vaccine candidate, Na-APR-1, in Washington, DC. Funding from the Michelson Medical Research Foundation is supporting the discovery of additional antigens to prevent hookworm and other intestinal helminths. Through our new collaboration with the HOOKVAC Consortium, we are working to expand manufacturing efforts in Europe, as well as clinical trials in Gabon, to prevent human hookworm.

15

Sabin PDP

Led by Drs. Peter Hotez and Maria Elena Bottazzi, the Sabin PDP is putting the need to control and eliminate NTDs more prominently onto the global health and vaccine development agenda.

Sabin continues to call for a schistosomiasis vaccine and is currently developing such an intervention through the Sabin PDP’s Schistosomiasis Vaccine Initiative. Last year, we manufactured a schistosomiasis vaccine antigen which will enter Phase 1 clinical trials, to be carried out at Baylor College of Medicine’s Vaccine and Treatment Evaluation Unit (VTEU) and supported by the National Institutes of Health. We are pushing the scientific frontier in other areas as well, by advancing discovery of five additional vaccines in various stages of development. In 2013, we kicked off the discovery of vaccine targets against ascariasis and trichuriasis. We also continued the preclinical phases for four other novel vaccine candidates: Chagas disease, cutaneous leishmaniasis, severe acute respiratory syndrome (SARS) and West Nile virus. Sabin PDP Director and Deputy Director, Drs. Peter Hotez and Maria Elena Bottazzi, respectively, are prominent champions for NTD advocacy and education efforts on a global level. In 2013, Dr. Hotez and other members of the Sabin PDP published more than 32 papers, articles, and opinion pieces and earned placements in more than 27 media outlets. A leading voice on the issue, Sabin is changing the global conversation – among academics, policymakers and health experts – about addressing NTDs in order to achieve broader health and development goals.

16

Sabin PDP

M HU

AN H O O K WOR

SC

M

PHASE 1 CLINICAL TRIALS

IA

SI

IS

200 million infected

S ,C

LE IS H MANI A

SIS

,S

A

EST

SE

US

,W

CHA

N I L E V I RU S

GAS DISEA

TA

O NE

RS

U

C AS

SIS / TRICHUR

OSOMIAS

MANUFACTURED ANTIGEN

600–700 million infected

IA AR

HIST

EXPLORATORY STAGE

more than one billion infected

CONTINUED PRECLINICAL PHASES

more than 15 million infected

17

Sabin PDP

Sabin’s Partners The Sabin PDP leverages the expertise of a large network of partners in the academic and R&D sectors to establish a new generation of vaccines that combat diseases of poverty — those afflictions that disproportionately affect poor communities.

NEW YORK BLOOD CENTER SABIN VACCINE INSTITUTE AND TEXAS CHILDREN’S HOSPITAL AT NIH BAYLOR COLLEGE National Institutes of Health OF MEDICINE

}

UNIVERSITY OF KANSAS



UNIVERSITY OF TEXAS MEDICAL BRANCH

GWU The George Washington University

ASCARIASIS/TRICHURIASIS CHAGAS DISEASES

CUTANEOUS LEISHMANIASIS HOOKWORM ONCHOCERCIASIS SCHISTOSOMIASIS

SEVERE ACUTE RESPIRATORY SYNDROME (SARS) WEST NILE VIRUS

18

CINESTAV Center for Research and Advanced Studies of the National Polytechnic Institute

BIRMEX

UADY Autonomous University of Yucatan

INSTITUTO BUTANTAN

FIOCRUZ Fundacao Oswaldo Cruz

Sabin PDP

 LSHTM London School of Hygiene and Tropical Medicine

PHARMIDEX PHARMACEUTICAL SERVICES LIMITED

UNIVERSITY OF NOTTINGHAM

AIGHD Amsterdam Institute for Global Health and Development

LUMC Q-BIOLOGICALS

Leiden University Medical Center

AMC UNIVERSITY OF TUEBINGEN

Academic Medical Center, University of Amsterdam

THE INSTITUTE OF PARASITE DISEASES Chinese Centers for Disease Control and Prevention

HÔPITAL ALBERT SCHWEITZER

JAMES COOK UNIVERSITY

19

Accelerating a

Movement to End Neglected Diseases

20

Global Network for Neglected Tropical Diseases

For the past seven years, the Global Network for Neglected Tropical Diseases (Global Network) has played a significant role in building the political support, funding and public awareness required to prioritize neglected tropical diseases (NTDs) as a global health threat and grow a movement dedicated to their control and elimination.

In that time, we have mobilized more than US $164 million and leveraged approximately US $1.4 billion in new resources for NTD and related development programs; helped create new mechanisms responding to NTDs at the global and regional levels; and elevated NTDs as a mainstream health issue to policymakers, prominent media outlets and the general public in multiple countries.

The Global Network is mobilizing new funding for NTD treatment programs.

In 2013, in particular, the Global Network led advocacy efforts with the U.S. government that resulted in a nearly 20 percent increase in funding for NTD programs. We also worked with partners to expand or develop NTD coalitions in key donor countries such as the U.S., Canada and Germany, achieved breakthrough regional resolutions to control and eliminate NTDs and built the case for integrating NTDs into other health sectors. Our strong collaboration with the World Health Organization (WHO) headquarters and regional offices around the world, as well as governments, continued in 2013 and contributed to the development of national NTD plans in more than 70 endemic countries. We expanded our conversations with the African Programme for Onchocerciasis Control (APOC) partners around its extension and expansion beyond 2015, while also coordinating with the World Bank to support consultation and integration of NTDs into the broader development projects of the International Development Association (IDA). The Global Network has strengthened ties with regional bodies such as the Secretariat of the Association of South East Asian Nations (ASEAN) to call attention to NTDs. As a result of our advocacy efforts, and alongside the leadership of the Philippines Department of Health, NTDs were included in two high-level health-related ASEAN meetings and recognized as a regional priority, signaling to donors that NTDs are a priority for multilateral institutions and calling attention to the highest levels of ASEAN member governments that NTD control and elimination require sufficient, sustainable and predictable allocation of human and financial resources, as outlined by the World Health Assembly. The ASEAN member states are now working on a plan to accelerate progress towards NTD control and elimination in the region.

21

Global Network for Neglected Tropical Diseases

The focus on NTDs in Africa also gained momentum. At the Sixth Conference of the African Union (AU) Ministers of Health in April 2013, the AU adopted the Continental Framework on the Control and Elimination of Neglected Tropical Diseases (NTDs) in Africa by 2020. In late 2013, the Global Network supported efforts in Germany to form a German NTD Coalition led by vfa, the German research-based pharmaceutical trade group. vfa collaborated with a consortium of German pharmaceutical companies, NGOs and academics to host an inaugural coalition meeting, a landmark event that underscores a broader movement in Germany to prioritize funding and political support for NTD programs. Building on a successful partnership with our first NTD Special Envoy, John A. Kufuor, President of the Republic of Ghana (2001-2009), we expanded and strengthened the NTD Special Envoy program with the introduction of two other former heads of state: Alvaro ArzĂş Irigoyen, President of Guatemala (1996-2000), and Ricardo Lagos Escobar, President of Chile (2000-2006), and the former Director of the Pan American Health Organization (PAHO), Dr. Mirta Roses Periago. Their voices and engagement have been critical in strengthening cross-sector and high-level relationships, raising awareness around NTDs and control and elimination programs, and building and maintaining momentum for the movement.

The Global Network is raising public awareness as part of its advocacy efforts toward control and elimination of NTDs.

Working with our NTD Special Envoys, the Global Network has supported efforts to increase the integration of NTD programs into other health sectors, such as water, sanitation and hygiene (WASH) and nutrition programs. In September 2013, President Kufuor participated in an event hosted by Johnson & Johnson, the Global Network, Children Without Worms, the Task Force for Global Health and the WHO in New York City during the 68th United Nations (UN) General Assembly. The event focused on multi-sectoral and innovative approaches for eliminating intestinal worms in children – key diseases undercutting many Millennium Development Goals (MDGs). Dr. Richard Besser, Chief Health and Medical Editor at ABC News, served as the event moderator and led a lively discussion that called for addressing NTDs as part of current MDG investments and urged their inclusion in the UN post-2015 development agenda. In October 2013, the Global Network hosted a development agency roundtable event in Berlin that brought together representatives from the U.S., UK, Japanese, German, Swiss and Brazilian governments, as well as leading health-focused organizations and pharmaceutical companies. The discussion resulted in broad consensus that NTDs are an important component of the poverty-reduction agenda and a critical aspect of solving the economic and social challenges associated with poverty.

22

Global Network for Neglected Tropical Diseases

The Global Network

POVERTY ALLEVIATION

CROSS-SECTOR COLLABORATION

HEALTH FUNDING

PARTNERS

DONATED MEDICINES

STAKEHOLDERS policy-makers, donor countries, endemic country counterparts, academics, health experts and advocates, bilateral and multilateral institutions, media, pharmaceutical industry, religious community, students, general public

available to control and treat these diseases.

Public awareness efforts are an important element of Sabin’s NTD advocacy efforts, and celebrity engagement through the END7 campaign is helping the Global Network reach new audiences. In 2013, END7’s advocacy video, “How to Shock a Celebrity,” enlisted the participation of global celebrities – well-known actors and musicians from the UK, U.S., India and South Africa – to showcase the effects of NTDs and the low-cost solutions

The video quickly gained more than half a million online views and helped END7 raise enough money to fund NTD treatment for millions of people. Through our social media campaigns, we have built a community of nearly 100,000 supporters, cultivated corporate partnerships and celebrity champions and shaped NTD policy debates, including a direct appeal to UN Secretary General Ban Ki-moon that called for making NTDs a priority topic in the post-2015 development agenda debate. Lastly, in January 2014, Abhishek Bachchan, one of the world’s best known Bollywood stars, joined the

Global Network’s END7 campaign as its first celebrity ambassador in India. This new engagement signals increased visibility and public education around the NTD burden in India, where more than 500 million people are at risk for one or more of the world’s five most prevalent NTDs: lymphatic filariasis, trachoma and soil transmitted helminths, including hookworm, roundworm and whipworm. 23

Building the Foundation for

Sustainable Immunization Programs

24

Vaccine Advocacy & Education

Sabin’s Vaccine Advocacy & Education program influences global and national health decision-makers, improving vaccine policy, financing and access. Over the past 10 years, Sabin’s Vaccine Advocacy & Education program has hosted conferences for more than 4,000 high-level decision-makers; trained more than 100 journalists to reach technical proficiency in vaccinology; and conducted vaccinology trainings for more than 150 practitioners to bridge the divide between the science of vaccines and the policies that support sound immunization programs.

Last year, we partnered with multilateral institutions such as the GAVI Alliance to strengthen global efforts to implement the Global Vaccine Action Plan (GVAP). We also worked closely with parliamentarians and ministry of health and finance officials to put in place the necessary financing and legislation to ensure sustainable access to life-saving vaccines. And, we supported pharmaceutical and national health leaders to prepare for the introduction of new vaccines for diseases like dengue fever. Through our Vaccine Advocacy & Education program, we are developing sustainable financing solutions for national immunization programs.

Through our Sustainable Immunization Financing (SIF) program, we have developed a niche expertise in the area of immunization program financing. Using an innovative approach that leverages collective action, the SIF program engages leaders in ministries of health and finance, parliaments and the private sector to develop sustainable financing solutions for national immunization programs. The goal is to reduce dependency and assure country ownership of programs. Among notable highlights for 2013, the SIF team closely collaborated with WHO in Geneva to analyze immunization expenditures reported by countries. The analysis produced a data model that predicts how much more funding countries will need to invest to be able to fully finance their immunization programs by 2020. The paper was published in a peer reviewed journal. An important aspect of the SIF program’s work is to encourage greater collaboration between ministries of health and finance and elected officials. Our country-based SIF senior program officers conduct hundreds of meetings each year with these national counterparts. Last year, the SIF team convened its second Sustainable Immunization Financing Colloquium in Dakar, Senegal, where more than 100 delegates from 17 countries gathered to discuss best advocacy practices, financing innovations and legislative work for immunization.

25

Vaccine Advocacy & Education

The Coalition against Typhoid (CaT) also organized the 8th International Conference on Typhoid Fever and Other Invasive Salmonelloses in coordination with its partners at the Bangladesh Pediatric Association, International Vaccine Institute and the International Centre for Diarrheal Research. With participation of over 500 clinicians, scientists, researchers and policy leaders, the conference strengthened communications between public health researchers and policy-makers at the national and regional levels in order to more strategically drive the research agenda on typhoid, paratyphoid and non-typhoidal salmonelloses. In June, Sabin formally launched the first-ever International Association of Immunization Managers (IAIM), a professional network focused on providing immunization managers with the necessary forum and tools to build management and leadership capacity. IAIM hosts conferences and webinars to share information and identify best practices, produces educational and advocacy materials, and hosts peer exchanges. As a major step forward for this historic initiative, IAIM won the support of the GAVI Alliance to fund membership to the Association for 73 immunization managers working in GAVI-eligible countries.

26

Sabin “20 Years” Original Gra

Vaccine Advocacy & Education

Paradigm Shift: Increasing Commitment to Country Ownership and Sustainability

PDP

Globe 1

bin “20 Years” Original Graphics N

TE

ON ATI GR

Poliovirus

AND EF

FIC

IEN

C

I

Partnership

I AT

A ON

ND K

NOWLED

GE

SH

Y

Sabin “20 Years” Original Graphics Globe 2

Meeting

A

UC

ED

NG

Globe 1

RI

abin “20 Years” Original Graphics Poliovirus

Measles Virus

Synthesis

PDP Meeting

Research

C

Globe 2

Globe 1

Poliovirus

O

UN

Y OW1NE R TRGlobe S

HI

Innovation

Sabin “20 Ye

Poliovirus

Measles Virus

P

Measles Virus

PA R Synthesis

Globe 2

PDP

Innovation

IN

TNERSHIPS

VAT NO

Partnership ION

Meeting

Scott Melamed 2014

AN

Y Globe 2 IT L DS I U S TAI NAB

Meeting

Globe 1

Research

Research

Partnership

Synthesis Synthesis

Globe 2

Innovation

Innovation

Scott Melamed 201

Synthesis

Scott Melamed 2014

27

Partnering Abroad: Sabin Foundation Europe

SABIN FOUNDATION EUROPE BOARD OF TRUSTEES

Morton P. Hyman Chairman James Beery Senior of Counsel, Covington & Burling LLP John Cummins Group Treasurer, Royal Bank of Scotland Jeremy Lefroy Member of Parliament, Stafford Constituency, House of Commons

28

Founded in 2011, Sabin Foundation Europe works to support R&D, advocacy efforts and treatment programs for vaccine-preventable and neglected tropical diseases. With leadership from the legislative, finance and legal sectors, Sabin Foundation Europe is spearheading efforts across Europe to promote health solutions for diseases of poverty.

Sabin Foundation Europe

Throughout 2013, Sabin Foundation Europe worked to strengthen relationships and collaborations with key civil society groups and parliamentary interest groups in the UK to raise public and political awareness of NTDs. These collaborations have played a supportive role in the UK Government’s continued commitment to NTDs through the 2012 London Declaration, which seeks to eliminate or control at least ten NTDs by 2020. Sabin Foundation Europe plays a vital role in supporting the direction and activities of the UK All Party Parliamentary Group on Malaria & NTDs (APPMG). This parliamentary interest group engages and supports the interests of UK parliamentarians on the issue of NTDs. Through engagement and support to the APPMG, both Sabin Vaccine Institute and Sabin Foundation Europe have continued to engage and raise political awareness of NTDs within the UK parliament, supporting the creation of new, and the strengthening of existing, parliamentary champions to support the UK Government's continued prioritization of NTDs. NEW BOARD MEMBER JAMES BEERY

In January 2014, James Beery, Senior of Counsel at Covington & Burling LLP, was elected to the Board. He brings with him extensive legal experience in the life sciences industry.

SABIN CITY GROUP

In partnership with Sabin, Sabin Foundation Europe helped launch Sabin City Group in 2013. This unique private sector engagement initiative aims to raise corporate awareness of the global NTD burden and its inextricable link to global poverty and the impact of treatment on extreme poverty alleviation. Leveraging public events and fundraising initiatives, Sabin City Group has focused its initial efforts on specifically addressing the NTD burden in Guyana, where an estimated 37,000 children are at risk of soil-transmitted helminths (STH), or intestinal parasites, and roughly 690,000 people are at risk of lymphatic filiariasis. By raising funds through corporate engagement, Sabin City Group will contribute to the completion of four national mass drug administration (MDA) programs against NTDs across Guyana. Through these strategic communications and advocacy efforts, Sabin City Group will support Sabin Foundation Europe’s work to elevate NTD control and elimination programs as a health priority among European regional level policy-makers and corporate partners.

29

Sabin Vaccine Institute 2013

Awards and Recognition Highlights from 2013

Awards and Appointments for Sabin Leadership

The Pan American Health Organization (PAHO) also recognized Dr. de Quadros’ career accomplishments with its prestigious Public Health Hero of the Americas award, its highest distinction, in 2014.

ten spot on YouTube’s list of “most popular videos on the web” and was selected to be showcased at the Cannes Lions International Festival of Creativity. 2013 Gold Medal Award In May 2013, Sabin presented the annual Albert B. Sabin Gold Medal Award to Dr. Anne Gershon for her pivotal role in combating the varicella zoster virus (VZV). Her research was critical to the widespread adoption of the varicella vaccine, which prevents chickenpox.

Sabin President, Dr. Peter Hotez, and Sabin Executive Vice President, Dr. Ciro de Quadros, were recognized by Vaccine Nation as top 50 most influential vaccine personalities. Dr. Hotez was also a recipient of the Elfenworks Award. Dr. Hotez delivered the David Packard lecture at the Uniformed Services University of the Health Sciences, the university’s most prestigious lectureship. Dr. Hotez was also honored as the annual Joseph F. Russo, M.D. Lecturer by the North American Society for Pediatric and Adolescent Gynecology, as well as the JV Irons Keynote Lecturer at the 63rd Annual James Steele Conference on Diseases in Nature Transmissible to Man. Dr. de Quadros was awarded the 2014 Geneva Forum for Health Award in recognition of the critical role that he played in improving health globally, including the eradication of polio in the Americas and worldwide. 30

Sabin Vaccine Institute Recognition and Appointments In 2013, Sabin received Charity Navigator’s highest 4-Star rating for the sixth consecutive year, a ranking that reflects our commitment to transparency, accountability and careful stewardship of funding. Only three percent of charities rated by Charity Navigator have received six consecutive 4-Star ratings. The END7 campaign’s “How to Shock a Celebrity” video won the 2013 DoGooder ImpactX Award sponsored by YouTube and Cisco Systems. The video also won PR Daily’s annual award for Best Public Service Announcement, held a top

Ten years after the vaccine was recommended in the U.S., the U.S. Centers for Disease Control and Prevention (CDC) reported as much as a 90 percent drop in chickenpox cases, a varicella-related hospital admission decline of 71 percent and a 97 percent drop in chickenpox deaths among those under 20.

Sabin Vaccine Institute 2013

Board of Trustees and Senior Leadership

Board of Trustees Morton P. Hyman Chairman Founder and CEO, MPH Enterprises, LLC

Rt. Hon. Baroness Helene Hayman, GBE Immediate Past Lord Speaker of the House of Lords, UK Parliament

Axel Hoos, M.D., Ph.D. Vice President, Oncology R&D, GlaxoSmithKline Pharmaceuticals

Paul Maddon, M.D., Ph.D. Founder, Progenics Pharmaceuticals

Peter L. Thoren

PROGRAM LEADERSHIP

Executive Vice President, Access Industries, Inc.

Maria Elena Bottazzi, Ph.D.

Michael E. Whitham Secretary and Treasurer Founding Partner, Whitham, Curtis, Christofferson & Cook

Heloisa Sabin

Professor of Business and Society, Stern School of Business, New York University

Gary Rosenthal Partner in the Sterling Group, L.P. Immediate Past Chairman of the Board of Trustees, Texas Children’s Hospital

Director, Policy, Global Network for Neglected Tropical Diseases

Senior Leadership

Peter Carrasco

EXECUTIVE LEADERSHIP

Director, International Association of Immunization Managers Secretariat

Michael W. Marine, Ambassador (Ret.) Chief Executive Officer President, Sabin Vaccine Institute Director, Sabin PDP, Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine

Neeraj Mistry, M.D., M.P.H. Managing Director, Global Network for Neglected Tropical Diseases

Brian Davis, C.P.A. Philip K. Russell, M.D. Past Chairman Major General, U.S. Army Medical Corps (Ret.)

Marc Shapiro Non-Executive Chairman, Chase Bank of Texas Immediate Past Chairman of the Board of Trustees, Baylor College of Medicine

Michelle K. Brooks

Honorary Trustee

Peter J. Hotez, M.D., Ph.D. Michael Posner

Deputy Director, Sabin PDP Director, Product Development, Sabin PDP, Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine

Chief Operating Officer

Ana Flavia Carvalho, M.B.A., M.P.H. Director, Special Projects, Vaccine Advocacy & Education

Marcia de Souza Lima, M.D., M.I.P.P. Director, Programs and Operations, Global Network for Neglected Tropical Diseases

David Diemert, M.D., FRCP(C) Director, Clinical Trials, Sabin PDP, The George Washington University

Richard J. Hatzfeld Director, Communications

Tara Hayward Director, Resource Development

M. Imran Khan, M.B.B.S, MSc, Ph.D. Director, Coalition against Typhoid Secretariat

Mike McQuestion, Ph.D., M.P.H. Director, Sustainable Immunization Financing 31

Sabin Vaccine Institute 2013 – Financial Report

Condensed Statement of Activities December 31, 2013 and 2012

Sabin's Board of Trustees and executive leadership are fully committed to responsible and effective stewardship of donor funding. For the sixth consecutive year, Sabin received Charity Navigator's highest rating for consistently executing our mission in a fiscally responsible way.

REVENUE AND SUPPORT

2013

2012

Grants, contributions and other support received

$20,073,409

$25,393,978

33,849,028

41,598,275

Investment income

37,134

31,516

TOTAL

53,959,571

67,023,769

20,425,905

19,401,006

2,162,559

2,111,781

TOTAL

22,588,464

21,512,787

EXCESS OF REVENUES, COMMITMENTS AND SUPPORT OVER EXPENSES

$31,371,107

$45,510,982

Future portion of grants as of year-end

EXPENSES

Program services General, administrative and fundraising

Only three percent of charities rated by Charity Navigator have received six consecutive 4-Star ratings.

2013 FUNCTIONAL EXPENSE ALLOCATION:

90%

Program Services 32

10% General, Administrative and Fundraising

Sabin Vaccine Institute 2013 – Financial Report

Condensed Statement of Financial Position December 31, 2013 and 2012

ASSETS

Cash, equivalents and other current assets

2013 2012

$14,942,971

$12,735,970

Investments

9,419,239

14,493,641

Other assets

68,059

72,324

TOTAL ASSETS

24,430,269

27,301,935

2,191,587

2,503,493

386,226

468,065

TOTAL LIABILITIES

2,577,813

2,971,558

Unrestricted net assets

2,303,747

2,138,685

Temporarily restricted net assets

19,548,709

22,191,692

TOTAL NET ASSETS

21,852,456

24,330,377

$24,430,269

$27,301,935

The financial statements presented have been summarized from Sabin's audited financial statements. Sabin's full audit report, completed by Rogers & Co, LLP, is available at www.sabin.org.

LIABILITIES AND NET ASSETS

Accounts payable and accrued expenses Other liabilities

TOTAL LIABILITIES AND NET ASSETS

2013 PROGRAM EXPENSE ALLOCATION:

31%

34%

35%

Vaccine Development

Vaccine Advocacy & Education

Global Network 33

Sabin Vaccine Institute 2013

Thank you To our partners, collaborators and contributors from around the world

A Aeras African Programme for Onchocerciasis Control African Union Commission African Union Mission to the United States Aga Khan University [Pakistan] Agence de Médecine Préventive [France] American Public Health Association American Society of Tropical Medicine and Hygiene Amsterdam Institute for Global Health and Development [The Netherlands] Ascension Health ASEAN Secretariat Asian Development Bank Association of Immunization Managers B Mr. Abhishek Bachchan Baylor College of Medicine Bharat Biotech [India] Bill & Melinda Gates Foundation bioMérieux BIRMEX [Mexico] Blavatnik Family Foundation Ms. Emily Blunt Brazilian Society of Immunizations [Brazil] büro svenja C Campbell Family Foundation Catholic Medical Mission Board CBM International CBM US Center for Research and Advanced Studies of the National Polytechnic Institute [Mexico] Center for Strategic and International Studies Center for Vaccine Development at the University of Maryland Ms. Yvonne Chaka Chaka Mr. William Chapman Chiapas State Government [Mexico] Children’s National Medical Center Children Without Worms Chinese Centers for Disease Control and Prevention, The Institute of Parasite Diseases [China] Ms. Priyanka Chopra Church’s Auxiliary for Social Action [India] Comic Relief

34

Communes et Villes Unies du Cameroun [Cameroon] Covington & Burling LLP Crucell [Switzerland] Mr. Richard Curtis D Dalberg Global Development Advisors Department for International Development [United Kingdom] Deworm the World initiative Drugs for Neglected Diseases Initiative Dubai Cares [United Arab Emirates] E The Earth Institute at Columbia University Effect: hope (The Leprosy Mission Canada) Eisai Co., Ltd. [Japan] EMI Music The END Fund European Centre for Disease Prevention and Control European Commission F Mr. Tom Felton Finlay Institute [Cuba] Fondation Mérieux [France] Fraunhofer Center for Molecular Biotechnology Frontier BioSciences, Inc. [China] Fundação Oswaldo Cruz [Brazil] Fundación Cinépolis [Mexico] Fundación Mundo Sano [Argentina] G GAVI Alliance The George Washington University, Department of Microbiology, Immunology and Tropical Medicine GlaxoSmithKline Global Health Partnership Initiative Global Health Technologies Coalition Government of the Municipality of Recife [Brazil] Governments and Parliaments of Argentina, Bhutan, Brazil, Burundi, Cambodia, Cameroon, Democratic Republic of Congo, Republic of Congo, East Timor, Ethiopia, Honduras, India, Indonesia, Kenya, Liberia, Madagascar, Mali, Mongolia, Nepal, the Netherlands, Nigeria, Panama, Philippines,

Senegal, Sierra Leone, South Africa, Sri Lanka, Thailand, Uganda, Vietnam H Mr. David Harris Harris LithoGraphics Helen Keller International Mr. Tom Hollander Hôpital Albert Schweitzer [Gabon] Hospital de Niños Dr. Ricardo Gutierrez [Argentina] Hospital de Niños Roberto del Río [Chile] Hudson Institute Mr. and Mrs. Morton Hyman I/J/K icddr,b [Bangladesh] IMA World Health Immune Design Corporation The Infectious Disease Research Institute Institut Pasteur Instituto Balseiro [Argentina] Instituto Butantan [Brazil] Instituto Carlos Slim de la Salud [Mexico] Instituto Conmemorativo Gorgas de Estudios de la Salud [Panama] Inter-American Development Bank International Trachoma Initiative International Vaccine Access Center IS GLOBAL James Cook University [Australia] Japan International Cooperation Agency The John A. Kufuor Foundation Johns Hopkins Bloomberg School of Public Health Join the Lights Mr. Michael Kuta L/M/N Leiden University Medical Center [The Netherlands] Lions Club of Nepal [Nepal] Liverpool School of Tropical Medicine [United Kingdom] London School of Hygiene and Tropical Medicine [United Kingdom] Merck & Co., Inc. Merck Serono Merieux Foundation Dr. Gary K. Michelson Michelson Medical Research Foundation New York Blood Center

Sabin Vaccine Institute 2013

Novartis Vaccines Institute for Global Health [Italy] Novartis Vaccines Latin America O Organization of American States Oxford University Clinical Research Unit at the Hospital for Tropical Diseases [Vietnam] Oxford Vaccine Group [United Kingdom] P/Q Pan American Health Organization PATH Pfizer Inc. Pharmidex Pharmaceutical Services, Limited [United Kingdom] Planty & Associates LLC Q-Biologicals [Belgium] Queensland Institute of Medical Research [Australia] R/S/T Mr. Eddie Redmayne Revolution Rx Rotary Clubs [Nepal, Cameroon] RTI International Sanitation and Water for All Sanofi Pasteur SA Santa Casa de São Paulo [Brazil] Save the Children Schistosomiasis Control Initiative Mr. and Mrs. Marvin and Donna Schwartz Secretaría de Salud [Mexico] Serum Institute of India Ltd. [India] Sevenly

Shantha Biotech [India] The Social Investment Consultancy SouthWest Electronic Energy Medical Research Institute Statoil Sterling Media Texas Children's Hospital The Task Force for Global Health U Uganda Local Governments Association [Uganda] UK Department for International Development [United Kingdom] UNICEF United Nations Relief and Works Agency Universidad Autónoma de la Yucatán [Mexico] Universidad Nacional de Colombia, Departamento de Salud Publica [Colombia] Universidade Federal da Bahia, Faculdade de Medicina [Brazil] University of Amsterdam, Academic Medical Center [The Netherlands] University of Kansas University of Notre Dame, Haiti Program University of Nottingham [United Kingdom] University of Otago, New Zealand [New Zealand] University of Pittsburgh University of Sydney [Australia] University of Tuebingen [Germany] University of Texas Medical Branch U.S. Agency for International Development U.S. Centers for Disease Control and Prevention

U.S. National Institutes of Health, Fogarty International Center U.S. National Institutes of Health, Laboratory of Malaria and Vector Research, Vector Molecular Biology Section U.S. National Institutes of Health, National Institute of Allergy and Infectious Diseases V/W vfa [Germany] Walter Reed Army Institute of Research WaterAid Webb Family Foundation Wellcome Trust [United Kingdom] Wellcome Trust Sanger Institute [United Kingdom] William Newkirk and Cheryl Tschanz Family Foundation Ms. Nicky Wimble World Health Organization World Health Organization Initiative for Vaccine Research World Health Organization, Regional Office for Africa World Health Organization, Regional Office for Europe World Health Organization, Regional Office for South-East Asia World Health Organization, Regional Office for the Eastern Mediterranean World Health Organization, Regional Office for the Western Pacific Wunderman [United Kingdom]

35

REMEMBERING A GLOBAL HEALTH HERO Dr. Ciro de Quadros, 1940 – 2014 With the passing of Dr. Ciro de Quadros on May 28, 2014, we said goodbye to a beloved colleague and friend and one of the greatest global health champions of the past 50 years. Ciro was a leading figure in efforts to eliminate polio and measles from the Americas and smallpox from Ethiopia, one of the disease’s remaining strongholds at the time. He pioneered a bold plan to vaccinate children in the most remote, war-torn and underdeveloped parts of Latin America and revolutionized 36

how immunization programs could be sustainably financed across the region. At Sabin, Ciro expanded upon his earlier work by advocating greater country ownership for immunization programs and encouraging improved coordination between development partners. Thanks to Ciro, millions of children around the world are alive today, and millions more have grown into healthy, productive adults. His imprint can be felt throughout Sabin and will continue to guide us in our ongoing efforts to deliver a healthier future to the planet’s poorest people.

Credits Photography / Cover Photo: Join the Lights / pg 2: Olivier Asselin / pg 5: Olivier Asselin, CDC Public Health Images, Alexandra Gordon, Esther Havens, Vivek Singh, University of Cincinnati, Evan Wilder / pg 6: Baylor College of Medicine / pg 7: Olivier Asselin / pg 8: Mo Scarpelli / pg 11: Olivier Asselin / pg 14: Olivier Asselin / pg 15: Mo Scarpelli / pg 16: Baylor College of Medicine / pg 17: CDC Public Health Images, Getty Images, Esther Havens / pg 20: Olivier Asselin / pg 21: Olivier Asselin / pg 22: Alexandra Gordon / pg 24: Join the Lights / pg 25: Mo Scarpelli / pg 26: Esther Havens / pg 28: Esther Havens / pg 30: Baylor College of Medicine; Evan Wilder / Page 35: Olivier Asselin / Page 36: Sabin Vaccine Institute; Design / BĂœRO SVENJA

Sabin Vaccine Institute 2000 Pennsylvania Avenue, NW Suite 7100 Washington, D.C. 20006 Phone : +1 202 842 5025 Web : www.sabin.org : www.facebook.com/sabinvaccine : @sabinvaccine


Sabin Vaccine Institute 2013 Annual Report